[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05676450":3,"trial-entities:NCT05676450":88,"trial-summary:NCT05676450":92},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":19,"study_type":20,"primary_purpose":21,"phases":22,"enrollment_info":24,"interventions":27,"primary_outcomes":34,"secondary_outcomes":38,"sex":39,"minimum_age":40,"maximum_age":41,"healthy_volunteers":14,"eligibility_criteria":42,"std_ages":46,"locations":49,"central_contacts":80,"overall_officials":82,"references":84,"see_also_links":85},"NCT05676450","2022-0603","Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas","RECRUITING","2026-08-31","2026-05","2026-05-20","2023-02-23","M.D. Anderson Cancer Center","OTHER",false,"To test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method.","Primary Objective:\n\n• To determine the feasibility and clinical utility of ctDNA in identifying actionable alterations and minimal residual disease for lymphoma patients across community centers in Texas.\n\nSecondary Objectives:\n\n* To provide useful prognostic information before treatment, assess molecular response at interim time points and residual disease at the end of therapy, and identify tumor-specific mutations\n* Levels of cfDNA and its association with both EFS and OS in patients receiving therapy",[18],"Lymphoma",[],"INTERVENTIONAL","DIAGNOSTIC",[23],"NA",{"count":25,"type":26},517,"ESTIMATED",[28],{"type":29,"name":30,"description":31,"armGroupLabels":32},"DIAGNOSTIC_TEST","cell-free DNA","Given by IV (vein)",[33],"cell-free DNA (cfDNA) samples",[35],{"measure":36,"timeFrame":37},"Overall Survival (OS)","through study completion; an average 1 year",[],"ALL","18 Years",null,{"inclusion":43,"exclusion":44,"raw_text":45},[],[],"Inclusion Criteria:\n\n1. Male\u002Ffemale patients who are at least 18 years of age on the day of informed consent signing.\n2. Patients must have a histologically documented diffuse large B-cell lymphoma requiring therapy.\n3. Provision of written informed consent for the study.\n4. Pregnant women not included\n5. Cognitively impaired adults are not included.\n\nExclusion Criteria:\n\nNone",[47,48],"ADULT","OLDER_ADULT",[50,67],{"facility":51,"status":7,"city":52,"state":53,"zip":54,"country":55,"contacts":56,"geoPoint":64},"MD Anderson Cancer Center","Houston","Texas","77030","United States",[57,62],{"name":58,"role":59,"phone":60,"email":61},"Chijioke Nze, MD","CONTACT","832-729-1752","CCNze@mdanderson.org",{"name":58,"role":63},"PRINCIPAL_INVESTIGATOR",{"lat":65,"lon":66},29.76328,-95.36327,{"facility":68,"status":7,"city":69,"state":53,"zip":70,"country":55,"contacts":71,"geoPoint":77},"Cancer Therapy and Research Center at The UT Health Science Center at San Antonio","San Antonio","78229",[72,76],{"name":73,"role":59,"phone":74,"email":75},"Adolfo Enriques Diaz Duque, MD","210-450-1209","diazduque@uthscsa.edu",{"name":73,"role":63},{"lat":78,"lon":79},29.42412,-98.49363,[81],{"name":58,"role":59,"phone":60,"email":61},[83],{"name":58,"affiliation":12,"role":63},[],[86],{"label":51,"url":87},"http:\u002F\u002Fwww.mdanderson.org",{"nct_id":4,"conditions":89,"biomarkers":91},[90],"Diffuse Large B-Cell Lymphoma",[],{"nct_id":4,"found":93,"summary":94,"prompt_version":104},true,{"design":95,"status":96,"heading":97,"summary":98,"follow_up":99,"word_count":100,"commitments":101,"compensation":102,"drugs_mentioned":103},"This interventional study plans to enroll 517 participants with diffuse large B-cell lymphoma. It is designed to test the feasibility and clinical utility of cell-free DNA.","completed","Cell-free DNA (cfDNA) for Lymphoma Patients in Texas Community Centers","This study is looking at how useful and practical it is to collect cell-free DNA (cfDNA) from lymphoma patients in community centers across Texas. cfDNA is DNA that travels freely in your blood and can be easily collected with a simple blood draw from your vein. Researchers want to see if cfDNA can help identify changes in your cancer and detect any remaining disease after treatment. The main goal is to see how long patients live overall (Overall Survival). You may be able to join if you are at least 18 years old, have diffuse large B-cell lymphoma requiring treatment, and can provide written consent. The study plans to enroll 517 participants.","Your overall survival will be measured through study completion, which is an average of 1 year.",112,"You would have blood samples taken to collect cell-free DNA (cfDNA) before and after your lymphoma treatment.","Not stated in the trial record.",[30],"v2"]